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Pere Barba,1 Jose Luis Pin˜ana,1 Rodrigo Martino,1 David Valcarcel,1 Alex Amoros,2
Anna Sureda,1 Javier Briones,1 Julio Delgado,1 Salut Brunet,1 Jorge Sierra1Patient comorbidities are being increasingly analyzed as predictors for outcome after hematopoietic stem
cell transplantation (HSCT), especially in allogeneic HSCT (Allo-HSCT). Researchers from Seattle have
recently developed several pretransplant scoring systems (hematopoietic cell transplantation comorbidity
index [HCT-CI] and the Pretransplantation Assessment of Mortality (PAM) model) from large sets of
HSCT recipients with the aim of improving nontransplant models, mainly the Charlson Comorbidity Index
(CCI). The validation of these comorbidity indexes in other institutions and in different disease and condi-
tioning-related settings is of interest to determine whether these models are potentially applicable in clinical
practice and in research settings. We performed a retrospective study in our institution including 194 con-
secutive reduced-intensity conditioning (RIC) AlloHSCT (allo-RIC) recipients to compare the predictive
value of the PAM score, CCI, the original HCT-CI, and the flexible HCT-CI using a different risk group strat-
ification. The median patient pretransplant scores for the HCT-CI, PAM, and CCI were 3.5, 22, and 0, respec-
tively. The flexible HCT-CI risk-scoring system (restratified as: low risk [LR] 0-3 points, intermediate risk [IR]
4-5 points, and high risk [HR].5 points) was the best predictor for nonreplapse mortality (NRM). The 100-
day and 2-year NRM incidence in these risk categories was 4% (95% confidence interval C.I. 2%-11%), 16%
(95% C.I. 9%-31%), and 29% (95% C.I. 19%-45%), respectively (P\.001), and 19% (95% C.I. 12%-28%), 33%
(95% C.I. 22%-49%), and 40% (95% C.I. 28%-56%), respectively (P5.01). However, we found no predictive
value for NRM using neither the original HCT-CI nor the PAM or CCI models. The better predictive capacity
for NRM of the flexible HCT-CI than PAM and CCI was confirmed with the c-statistics (c-statistics of 0.672,
0.634, and 0.595, respectively). Regarding the 2-year overall survival (OS), the flexible HCT-CI score cate-
gories were also associated with the highest predictive HR. In conclusion, our single-center study suggests
that the flexible HCT-CI is a good predictor of 2-year NRM and survival after an allo-RIC.
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Knowledge of the impact of specific pretransplant
variables on the risk of mortality, especially nonrelapse
mortality (NRM), after an allogeneic hematopoietic
stem cell transplantation (Allo-HSCT) is of utmost
importance in estimating which patients may benefit
most from these high-risk procedures. Disease, trans-
plant procedure, and patient-specific variables have
all been analyzed for their impact on survival after an
Allo-HSCT [1]. However, it has been historically
very difficult to generate a reproducible and easy pa-
tient comorbidity model for predicting mortality after
these procedures. Recently, the impact of specific un-
derlying comorbidities on survival and NRM has413
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bidity index (CCI) [2] was developed to predict survival
after various therapies in cancer patients and those
with other serious chronic conditions, but it was not
developed for HSCT recipients. Thus, great efforts
are being placed in developing more specific HSCT
models. In recent years, researchers from Seattle
[3,4] developed 2 HSCT-specific indexes that quantify
the impact of patients’ comorbidities on posttransplant
outcome. In 2005, Sorror et al. [3] developed and val-
idated the most popular of these models, which is
known as the hematopoietic cell transplantation co-
morbidity index (HCT-CI), a modification of the
CCI, which includes 17 pretransplant comorbidities
assigned a weighted semiquantitative impact on out-
comes based on the predictive hazard ratio (HR) for
NRM. More recently, Parimon et al. [4] developed
the Pretransplantation Assessment of Mortality
(PAM) score, which included pretransplant variables
such as patient age, donor type, and the conditioning
regimen in addition to patients’ comorbidities. Since
its creation, various studies have attempted to validate
theHCT-CI in different disease-specific settings (such
as acute myelogenous leukemia [AML] [5,6] and lym-
phoproliferative disorders [7,8]), stem cell sources
(umbilical cord blood [UCB] HSCT [9]), and in autol-
ogous HSCT [10,11]. The ability of this index to pre-
dict survival and NRM has differed between studies,
and, in some studies, its predictive potential has not
been confirmed [9,12].
Patients who receive reduced-intensity conditioning
(RIC) for Allo-HSCT (allo-RIC) are prone to have
more significant comorbidities than recipients of a con-
ventional high-dose conditioning regimen, as confirmed
in recent studies [12,13]. In the RIC setting, the impact
of the comorbiditymodels on survival andNRMhas not
been extensively analyzed, and their validation in inde-
pendent cohorts of allo-RIC recipients is needed. In this
retrospective study, we investigated the value of 3 risk-
scoring systems (CCI, HCT-CI using a flexible stratifi-
cation, and the PAM score) in predicting transplant out-
comes in a cohort of allo-RIC patients.PATIENTS AND METHODS
The study included 194 consecutive adult patients
who received an allo-RIC in our institution between
January 1999 and December 2006. The transplant
protocols were approved by our national and local
ethics committees, and patients gave written informed
consent for their inclusion in each protocol.
Conditioning Regimen and Graft-versus-Host
Disease and Infectious Prophylaxis
Conditioning for all patients included fludarabine
(Flu) 150 mg/m2 in combination with melphalan (Mel)70-140 mg/m2 (lymphoid malignancies and multiple
myeloma [MM]), busulfan (Bu) 8-10 mg/kg (myeloid
malignancies), cyclophosphamide (Cy) 120 mg/kg (solid
malignancies), or low-dose total body irradiation (TBI)
2 Gy (chronic myelogenous leukemia [CML]). Graft-
versus-host disease (GVHD) prophylaxis included cy-
closporine A (CsA) plus methotrexate (MTX) or CsA
plus mycophenolate mophetil (MMF). CsA was started
on day 27 at a dose adjusted to blood levels (between
200 and 300 mg/mL). MTX was administered on days
11, 13, and 16 (10 mg/m2, followed by folinic acid
rescue). MMF was started on day 0 (at least 10 hours
after infusion of progenitors) at a dose of 15 mg/kg
every 8 hours and continued until day 130. Alemtuzu-
mab or antithymocyte globulin (ATG) were given to
recipients of HLA-mismatched related donors (n5 2)
or mismatched unrelated donors (n5 13). In addition,
patients with Hodgkin disease (HD) with matched
unrelated donors (MUD) (n5 7) received ATG as part
of a clinical trial, and2patientswith chronic lymphocytic
leukemia (CLL) and 1 with follicular lymphoma with
MUD received alemtuzumab also as part of a clinical
trial.
Acyclovir, fluconazole, and ciprofloxacin were ad-
ministered during the first 2 weeks posttransplant as
infectious prophylaxis. Cytomegalovirus (CMV) infec-
tion screening for guiding preemptive therapy was per-
formed using pp65 antigenemia (until February 2002)
or quantitative polymerase chain reaction (PCR) (since
February 2002), as reported elsewhere in detail [14].
Disease Risk Status Assessment
Disease status was categorized as low, intermedi-
ate, or high risk as previously described [4]. Low-risk
disease status included CML in first chronic phase,
aplastic anemia (AA), acute leukemia in first complete
remission (CR1), and untreated low-risk myelodys-
plastic syndrome (MDS). Intermediate-risk status in-
cluded CML in accelerated phase, acute leukemia in
second CR, Hodgkin and non-Hodgkin lymphoma
(HL, NHL) in CR1 or CR2, and CLL. High-risk sta-
tus included acute leukemia and lymphoma not in-
cluded in the intermediate risk category, multiple
myeloma (MM), and solid tumors.
Comorbidity Information
The patients’ charts were reviewed to capture in
detail all the information needed for calculating the
comorbidity indexes, and the final comorbidity score
for each index was calculated by adding the different
conditions’ scores, as defined in each model [2-4], ex-
cept for the leukemia and lymphoma categories in the
CCI, which were not considered because all of our
patients had hematologic malignancies and CCI defi-
nitions lack details on which specific malignancies
were originally included in this category. According
Biol Blood Marrow Transplant 16:413-420, 2010 415Validation of Comorbidity Indexes in Allo-RICto the number of patients with each score, we grouped
our patients into 3 risk categories (low, intermediate,
and high risk). With the aim of including a sufficient
number of patients in each risk group we decided
to use a flexible HCT-CI, in which patients were
classified into low (score 0-3), intermediate (4-5), and
high risk ($6), which include 50%, 25%, and 25% of
the patients, respectively. These cutoff points differ
from the original HCT-CI (stratified as low risk, score
0; intermediate risk, score 1 and 2; and high risk, score
$3) which was also included for comparative purposes.
For the PAM score, patients were classified into low
(score 9-16), intermediate (17-23), high (24-30), or
very high (.30) risk categories [4], with a score of 1
for all patients in the category Conditioning intensity.
For the CCI [2], patients were grouped into low-
(score 0), intermediate- (1-2), and high- ($3) risk
categories.
Laboratory test results used for calculating these
indexes were performed within 7 days before the be-
ginning of the conditioning regimen, and pulmonary
function tests and left ventricular ejection fraction
were measured in the month before the transplant.Endpoints and Statistical analysis
The primary endpoint of the study was to analyze
the predictive value of the 3 pretransplant predic-
tive models on NRM and survival in our allo-RIC
population. A secondary objective was to describe the
most frequent comorbidities in patients undergoing
allo-RIC.
Overall survival (OS) and NRM were defined as
the time from day 0 of the transplant to death from
any cause and death from any cause but relapse, respec-
tively. The incidence of acute GVHD (aGVHD),
chronic GVHD (cGVHD), NRM, and relapse were
calculated using cumulative incidence estimates, tak-
ing into account the competing risk model [15,16].
The probability of OS was estimated from the time
of transplantation using Kaplan-Meier curves [17]
and compared using the Tarone-ware and the Log
rank tests, 2 methods widely used to compare survival
distributions [18]. Comparison between baseline char-
acteristics between different groups of patients was
performed using 2 2 tables made by means of chi-
squared or Fisher’s exact t-tests. Continuous variables
were compared by means of the Wilcoxon rank sum
test. Likelihood ratio statistics from proportional
hazard models were computed for the study events
over the first 2 years post-Allo-HSCT. The c-statistic
was calculated to estimate the predictive capacity of
each index for the analyzed transplant outcomes, as
previously described [19]. The c-statistic ranges from
0.5 (random correlation) to 1 (perfect correlation),
and a model with 0.65 is useful in predicting response
of individual patients [3]. In addition, univariate Coxregression model was used to estimate the impact of
the different pretransplant predictive models on
NRM and OS, and a significance level of P # .05
was required.
Of note, because the major objective of this study
was to analyze the potential utility of the flexible
HCT-CI in predicting posttransplant outcomes, any
potential associations between this index and other
potentially relevant pretransplantation/transplanta-
tion characteristics would lead to unreliable statistical
findings. Thus, potential associations of the flexible
HCT-CI risk groups with patient age, donor type,
performance status, conditioning regimen, GVHD
prophylaxis, disease status, CMV serostatus, hemato-
poietic recovery, incidence of aGVHD and cGVHD,
and disease relapse were excluded using the general-
ized estimating equation method and logistic regres-
sion (details not shown).
All statistical analyses were performed using SPSS
version 15.0 (SPSS, Chicago, IL), with the exception of
the cumulative incidence analyses, which were carried
out with NCSS 2004 (Number Cruncher Statistical
System, Kaysville, UT).RESULTS
Patient Characteristics
All 194 consecutive patients who received an allo-
RIC in our institution were included in the study, and
the pretransplant characteristics are shown in Table 1.
Ninety percent of the patients received an allo-RIC
from an HLA identical sibling donor, mainly for mye-
loid malignancies and NHL. Thirty-nine percent of
the patients had received a prior autologous SCT.
The median age at transplantation was 54 years, and
only 13 patients (7%) had low ECOG performance
status (.1). The median posttransplantation follow-
up for survivors was 48 months.Distribution of Comorbidity Indexes and
Comorbidity Conditions
The frequency of each comorbidity in our patient
cohort as defined in the 3 models validated herein is
shown in Figure 1. Median scores for the HCT-CI,
PAM, and CCI in our population were 3.5 (range: 0-
13), 22 (range: 7-37), and 0 (range: 0-6), respectively.
The distribution of patients according to each index
is summarized in Table 2, which differentiates the pa-
tient distribution according to the original HCT-CI
risk group stratification from the flexible stratification
used in the current study because of the very small
numbers of patients in 2 of the 3 risk groups when
categorized by the original HCT-CI [3] (low risk5 13
patients, intermediate risk5 24 patients, high risk5
157 patients).
Table 1. Patient Characteristics and Transplant Outcomes
Median age, years (range) 54 (18-71)
Sex male, n (%) 122 (63)
 Female donor to male recipient 52 (27)
Underlying disease, n (%)
 AML or MDS-MPS 63 (32)
 Hodgkin lymphoma 27 (14)
 NHL and CLL 55 (28)
 Multiple Myeloma 29 (15)
 Others 20 (10)
Advanced disease status at HSCT*, n (%) 118 (60)
Recipient/Donor CMV serology, n (%)
 Recipient and donor negative 16 (8)
 Recipient and/or donor positive 178 (92)
Donor type, n (%)
 HLA identical sibling 153 (79)
 Alternative (VUD or MM related) 41 (21)
Conditioning regimen, n (%)
 Fludarabine-Melphalan 121 (62)
 Fludarabine-Busulfan 62 (32)
Peripheral blood stem cells, n (%) 181 (93)
Alemtuzumab or ATG based conditioning, n (%) 25 (13)
GVHD prophylaxis, n (%)
 CsA-MTX 135 (70)
 CsA-MMF 53 (27)
Graft content, CD34 +109/kg, median (range) 6.3 (1.3-15.6)
Transplant outcomes
Cum. Inc. acute GVHD, % (95% C.I.)
 Grade I-IV 55 (48-63)
 Grade II-IV 29 (23-36)
Cum. Inc. chronic GVHD at 2 years, % (95% C.I.) 70 (63-78)
Cum. Inc. relapse at 2 years, % (95% C.I.) 35 (28-42)
Cum. Inc. NRM at 2 years, % (95% C.I.) 27 (22-34)
Probability of 2-year overall survival, % (95% C.I.) 52 (45-59)
Median follow-up for survivors, days (range) 1396 (46-2947)
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syn-
drome; MPS, myeloproliferative syndrome; NHL, Non-Hodgkin lym-
phoma; CLL, chronic lymphocytic leukemia; n, number; HSCT,
hematopoietic stem cell transplantation; CsA, cyclosporine A; MTX,
methotrexate; MMF, micophenolate mophetil; GVHD, graft-versus-
host disease; CI, confidence interval; Cum. Inc., cumulative incidence;
CMV, cytomegalovirus; VUD, volunteer unrelated donor; MM, HLAmis-
match; ATG, antithymocyte globulin.
*Advanced (or nonearly) disease status was considered in patients with
acute leukemia in $2nd complete remission (CR), myeloproliferative
disease in$2nd chronic phase and in accelerated or blast phase, Hodg-
kin disease in $3rd remission or with partial remission (PR), follicular
lymphoma $3rd CR, large B cell lymphoma or multiple myeloma
$2nd CR or PR and solid tumors. Patients with PR or persistent disease
at transplantation (except for myeloma) were also considered as ad-
vanced disease status.
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ing to the specific definition used for each comorbid-
ity in each classification system is shown in Figure 1.
Regardless of the specific definition used, the most
frequent comorbidity was pulmonary impairment
(85% according to HCT-CI, 82% according to
PAM score— 35% with low forced expiratory volume
in 1 second (FEV1) and normal carbon monoxide dif-
fusing capacity [DLCO], 20% with normal FEV1 and
low DLCO, and 26% with low FEV1 and low
DLCO—and 20% according to CCI). From the
164 patients with pulmonary disease according to
the HCT-CI, 80 patients (49%) had severe pulmo-
nary impairment, whereas 84 patients (51%) had
moderate lung disease.Outcome
GVHD
aGVHD developed in 101 (54%) patients, with
a day 1120 cumulative incidence of grade II-IV
aGvHD of 29% (95% C.I. 23%-36%). Of the 142 pa-
tients evaluable for cGVHD, 100 developed cGVHD,
with a 4-year cumulative incidence of 52% (95% C.I.
45%-59%).
NRM
The 100-day and 2-year incidences of NRM were
12% (95% C.I. 9%-19%) and 27% (95% C.I. 22%-
34%), respectively. The most common causes of
NRM were GVHD and infections (27 patients died
from GVHD with infection, 17 from GVHD without
infection, and 9 from infectionwithoutGVHD). In uni-
variate analysis, the flexible HCT-CI risk groups
showed an impact on the early and late NRM, as shown
in Table 2 and Figure 2. Although both the original
HCT-CI risk group stratification and the flexible strat-
ification appeared somewhat discriminative (especially
in early NRM), we chose to use the flexible version be-
cause of the greater number of patients included in the
low and intermediate risk groups, as shown in Table 2.
With this stratification, the flexible HCT-CI low-, in-
termediate-, and high-risk groups had a day 1100
NRM of 4%, 16%, and 29% (P\ .01), respectively,
and a 2-yearNRMof 19%, 33%, and 40%, respectively
(P5 .01). However, we found no impact on early or late
NRMwhen using the PAMandCCI risk groupmodels,
eitherwith theoriginal stratification (Table 2) orwith al-
ternative stratifications (data not shown). In addition,
the c-statistic for the flexible HCT-CI, PAM, and CCI
for 2-year NRM was 0.672, 0.634, and 0.595, respec-
tively, showing that the former had the greatest predic-
tive value for detecting increases in NRM.
OS
The 2-year probability of OS was 51%. In univar-
iate analysis, only the flexible HCT-CI risk groups
showed an impact on OS (shown in Table 2 and Fig-
ure 3), which was 63%, 47%, and 31% in the low- in-
termediate-, and high-risk groups, respectively (P\
.001). Again, the original HCT-CI, PAM, and CCI
risk group models showed no impact on OS, although
the PAM showed a trend (P5 .11). Again, the c-statistic
values for the flexible HCT-CI, PAM, and CCI with
respect to 2-year OS were 0.731, 0.680, and 0.672, re-
spectively, being the highest with the HCT-CI.DISCUSSION
The introduction of RIC transplants has been re-
peatedly stated to be a major factor for the increasing
number of Allo-HSCT performed in elderly and
Figure 1. Distribution of comorbidities according to HCT-CI (A), PAM score (B), and CCI (C).
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myeloablative (MA) conditioning because of an ex-
pected high conditioning-related toxicity and very
high early NRM. Furthermore, these comorbidities
may also lead to high late NRM, because they are
not expected to improve along the posttransplant pe-
riod. Thus, it becomes imperative to analyze whether
the indexes developed for other patient groups and
transplant types are also applicable to an independent
cohort of allo-RIC recipients, with much higher base-
line comorbidities. If so, in the future such indexes
might be included in patient decision-making algo-
rithms, both for conventional high-dose and also
allo-RIC procedures. However, some authors have
already shown that the HCT-CI, the most widely
studied index, may not be useful for very different
Allo-HSCT settings, such as adult cord blood trans-
plantation (CBT) [8] or in a heterogeneous cohort of
Allo-HSCT procedures [13]. Thus, a possible weak-ness of all current models may depend on not having
the same impact in different patient and transplant
populations.
Our patient characteristics confirm the high rate of
comorbidities in an allo-RIC population. As in previ-
ous studies [3,7,9], the most common comorbidity
was moderate or severe pulmonary impairment,
whereas cardiac and hepatic abnormalities and diabe-
tes were also common, as shown in Figure 1. Of
note, the frequency of the various comorbidities
largely depends on the exact definition established in
each comorbidity index, which differ significantly for
most major organs. For instance, 21 patients (11%)
in our series had moderate or severe hepatic abnormal-
ities according to the HCT-CI definitions, whereas
none met the much stricter criteria used in the CCI.
The limited capacity of the CCI to capture the less
severe abnormalities commonly seen in Allo-HSCT
recipients has been previously pointed out [3,13], and
Table 2. ComorbidityGroups as Stratified by Scores of theHCT-CI (Original and Flexible Stratifications), the PAMand theCCI and
the Observed Nonrelapse Mortality and Overall Survival by Risk Groups
Num.
Patients (%)
Day +100 NRM 2-year NRM 2-year OS
Incidence
(95% C.I.) Univariate P
Incidence
(95% C.I.) Univariate P
Probability
(95% C.I.) Univariate P
Original HCT-CI risk groups
 Low (score 0) 13 (7) 0 (0-0) 15 (4-55) 54 (40-67) .55
 Intermediate (score 1-2) 34 (18) 6 (2-24) <.001 18 (9-36) .43 59 (50-68)
 High (score >2) 147 (76) 16 (11-24) .36 31 (24-39) .52 49 (45-53)
Flexible HCT-CI risk groups
 Low (score 0-3) 97 (50) 4 (2-11) — 19 (12-28) — 63 (58-68)
 Intermediate (score 4-5) 49 (25) 16 (9-31) .008 33 (22-49) .04 47 (40-54) <.001
 High (score >5) 48 (25) 29 (19-45) .001 40 (28-56) .01 31 (24-38) <.01
Pretransplantation Assessment
of Mortality (PAM)
 Low (8-15) 13 (7) 8 (1-51) — 23 (9-62) — 77 (65-89) .11
 Intermediate (16-22) 87 (45) 10 (6-19) .7 22 (15-32) .40 56 (51-61)
 High (23-29) 81 (42) 19 (12-29) .16 33 (24-45) .44 43 (37-49)
 Very high >(>05 30) 13 (7) 8 (1-51) .7 31 (14-70) .90 38 (24-52)
Chalrson Comorbidity Index (CCI)
 0 100 (52) 11 (6-19) — 26 (19-36) — 56 (51-61) .35
 1-2 77 (40) 16 (10-27) .35 27 (18-49) .57 47 (41-53)
 > 2 17 (9) 20 (7-54) .69 35 (25-99) .49 41 (29-53)
HCT-CI indicates Hematopoietic Cell Comorbidity Index; C.I., confidence interval; NRM, nonrelapse mortality; OS, overall survival.
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setting, because we found a median CCI score of
0 (that is, no comorbidities by the CCI), with\10%
of the patients being in a high-risk category, defined
by a score of only .2 points. However, the high pro-
portion of patients in the CCI low risk category (score
0) includes both completely fit patients and those with
‘‘mild’’ comorbidities (not captured with the CCI),
which may have prognostic impact when redefined
by the HCT-CI criteria.
The PAM score includes some true comorbidity
conditions (such as renal failure and respiratory impair-
ment), but also several noncomorbidity variables, such
as age, donor type, and conditioning regimen. We
failed to find any correlation between the PAM score0
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intermediate-risk groups by the original HCT-CI cri-
teria), we modified the threshold levels for the transi-
tion from low- to intermediate-risk and intermediate-
to high-risk categories, and the most useful recoding
was a score of 0-3 for the low-risk group, a score of
4-5 for the intermediate-risk group, and a score of .5
for the high-risk group. This flexible HCT-CI ap-
peared a better predictive tool than the original
HCT-CI for both NRM and OS (Table 2). This high-
lights how the HCT-CI and other scoring systems
should have the flexibility to allow stratification of
risk groups based on the balanced distribution of the
characteristics of the patient cohorts studied.
We also explored the value of the original and flex-
ible HCT-CI in predicting other transplant outcomes,
but there was no impact of this index in univariate anal-
ysis on the incidence of aGVHD, suggesting that it is
indeed a better predictor of NRM and OS than other
transplant outcomes.
The group of experts who developed the HCT-CI
recently recommended the validation of the currently
available comorbidity models by comparing these in-
dexes in relatively homogeneous patient populations
with adequate numbers of tested events [21]. Because
we focused the validation in an allo-RIC setting and
had no missing data to calculate all the comorbidity
categories, the results described herein support the
value of objectively calculated comorbidity scores
for future decision making in an allo-RIC setting,
although the exact thresholds for classifying the risk
groups may differ in various settings. Further com-
plexity comes from the fact that the truly independent
impact of each type of comorbidity must be deter-
mined by integrating them in a more comprehensive
and complex pretransplant assessment. Undoubtedly,
individual comorbidities do not simply have an addi-
tive effect in determining outcome, but rather interact
with other patient, disease, transplant-related, social,
and psychological characteristics. Of course, the cur-
rent study cannot address these issues.
Thus, a flexible HCT-CI proved to be a strong in-
dependent predictor of NRM and OS in the studied
allo-RIC cohort, and continued international efforts
to develop robust comorbidity scores appear war-
ranted. Patients, clinicians, and researchers will un-
doubtedly welcome new tools to improve the
selection of the best candidates for a high-risk proce-
dure such as an Allo-HSCT, even in the setting of
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